2 results
Approved WMOPending
The primary objective is to determine the efficacy of the neuroprotectant, nerinetide in:• Reducing global disability in participants with acute ischemic stroke (AIS)
Approved WMORecruiting
Primary objective: To evaluate the efficacy of inebilizumab in reducing the risk of a disease flare in patients with IgG4-RD.Secondary objectives:• To evaluate the safety and tolerability of inebilizumab in patients with IgG4-RD.• To evaluate the…